Saturday 17 October 2026 Export SOLV’s income statement to Excel — free account

Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%

Follow SOLV

Alert me

Market cap: $15.0B
P/E: 10.4×
Fwd P/E: 39.0×
Dividend yield: —
F-score: 5/9
Altman Z: 2.22
Beneish M: −2.07
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 16.54%

Capital & Financial Ratios $m

Market Cap 14,960.00

Revenue 8,310.00

Net Income 1,434.00

Free Cash Flow (118.00)

Net Debt 4,883.00

Current Ratio 1.02

Debt/Equity 1.10

P/E ratio 10.44

Fwd P/E 39.00

P/S ratio 1.78

P/B ratio 3.09

Past 5Y EPS Growth —

This Y EPS Growth 17.18%

Next Y EPS Growth 2.44%

Next Y revenue growth (1.14%)

Next 5Y EPS Growth 9.70%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	194	762	878	403
Receivables	1,313	1,229	1,184	1,432
Inventory	857	965	1,066	1,040
Other	155	293	731	865
	2,519	3,249	3,859	3,741

	2023	2024	2025	Q'26
Payables	477	618	687	701
ST’ Debt	—	200	—	506
Other	677	1,041	1,393	1,528
	1,728	2,703	3,136	3,663

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	0.79%
Cash Flow	—	—	(39.65%)
Earnings	—	—	5.03%
Book Value	—	—	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2,007	2,209	—	—	—
’25	2,070	2,161	2,096	1,998	8,325
’24	2,016	2,081	2,082	2,075	8,254
’23	2,011	2,076	2,074	2,036	8,197

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(189)	227	—	—	—
’25	29	169	76	95	369
’24	442	355	169	219	1,185
’23	509	366	493	547	1,915

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(273)	144	—	—	—
’25	(80)	59	(21)	32	(10)
’24	340	297	76	92	805
’23	444	295	427	459	1,625

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.07	0.53	—	—	—
’25	0.78	0.51	7.22	0.36	8.88
’24	1.37	0.51	0.70	0.17	2.76
’23	1.70	1.86	2.66	1.58	7.79

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	47.16	60.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	96.05	88.20
People
People	Employees	—	—	—	—	—	—	—	—	22,000	20,000
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.00	0.38	0.42
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	8,130	8,197	8,254	8,325
	Gross margin, %	—	—	—	—	—	—	57.75	57.25	55.65	53.47
	EBT	—	—	—	—	—	—	1,692	1,667	605	1,713
	EBT margin, %	—	—	—	—	—	—	20.81	20.34	7.33	20.58
	Net income	—	—	—	—	—	—	1,343	1,346	479	1,556
	Depreciation	—	—	—	—	—	—	578	561	555	489
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	47.08	47.46	47.66	47.82
	Earnings	—	—	—	—	—	—	7.78	7.79	2.77	8.94
	Cash flow	—	—	—	—	—	—	9.72	11.09	6.84	2.12
	Capex	—	—	—	—	—	—	(1.45)	(1.68)	(2.19)	(2.18)
	Free cash flow	—	—	—	—	—	—	8.27	9.41	4.65	(0.06)
	Book value	—	—	—	—	—	—	0.00	67.55	17.08	29.00
	Shares, m	—	—	—	—	—	—	173	173	173	174
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	10.26	10.26	24.02	8.87
	P/S	—	—	—	—	—	—	1.69	1.69	1.39	1.66
	P/B	—	—	—	—	—	—	1.18	1.18	3.87	2.73
	EV/Sales	—	—	—	—	—	—	1.66	1.66	2.26	2.17
	EV/FCF	—	—	—	—	—	—	8.38	8.38	23.22	(1,805.27)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	1,679	1,915	1,185	369
	Capex	—	—	—	—	—	—	(251)	(290)	(380)	(379)
	Free cash flow	—	—	—	—	—	—	1,428	1,625	805	(10)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	—	791	546	723
	Total debt	—	—	—	—	—	—	—	—	8,010	5,035
	Net debt	—	—	—	—	—	—	—	(194)	7,248	4,157
	Shareholders’ equity	—	—	—	—	—	—	—	11,666	2,959	5,049
Returns, %
Returns, %	ROA	—	—	—	—	—	—	0.00	19.31	3.37	10.82
	ROIC	—	—	—	—	—	—	0.00	9.22	6.34	14.81
	ROE	—	—	—	—	—	—	0.00	0.00	6.55	38.86

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALC Alcon	$32.1B	50.5×	31.0×	+8.74% (above 0%: growing)	n/m	−0.54% (below 0%: shrinking)	59.33%	0.39%	Compare
WST West Pharmaceutical Services, Inc.	$27.0B	48.7×	37.3×	+13.80% (above 0%: growing)	+19.23% (above 0%: growing)	−20.71% (below 0%: shrinking)	37.74%	20.53%	Compare
SOLV Solventum Corporation	$15.0B	10.4×	39.0×	+2.22% (above 0%: growing)	+1.92% (above 0%: growing)	+144.07% (above 0%: growing)	58.22%	8.19%
BAX Baxter International Inc.	$13.3B	— (loss-making)	44.7×	+5.34% (above 0%: growing)	+33.33% (above 0%: growing)	+119.48% (above 0%: growing)	34.86%	7.33%	Compare
RGEN Repligen Corporation	$11.7B	234×	112×	+11.93% (above 0%: growing)	−65.38% (below 0%: shrinking)	+27.10% (above 0%: growing)	53.91%	6.85%	Compare
COO The Cooper Companies, Inc.	$10.9B	19.8×	28.7×	+0.56% (above 0%: growing)	+357.14% (above 0%: growing)	+65.96% (above 0%: growing)	66.77%	20.82%	Compare
AVTR Avantor, Inc.	$10.9B	— (loss-making)	25.5×	+0.53% (above 0%: growing)	−33.33% (below 0%: shrinking)	+12.66% (above 0%: growing)	31.73%	7.20%	Compare
ALGN Align Technology, Inc.	$10.6B	25.6×	20.7×	+4.32% (above 0%: growing)	−12.21% (below 0%: shrinking)	+85.77% (above 0%: growing)	71.71%	14.58%	Compare
ATR AptarGroup, Inc.	$7.9B	22.2×	21.0×	+6.26% (above 0%: growing)	−18.34% (below 0%: shrinking)	−23.07% (below 0%: shrinking)	35.61%	12.34%	Compare
Median of peers	$11.3B	37.1×	29.9×	+5.80%	−12.21%	+19.88%	45.83%	9.83%

All 55 Medical Instruments & Supplies stocks →

Solventum Corporation (SOLV) key facts

Strength: Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
Strength: Net income was $1.6 billion, or $8.94 per share (basic), a net margin of 18.7%.
Solventum Corporation (SOLV) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, SOLV traded at $85.81, a market capitalization of $15.0 billion.
At that price the stock trades at 10.4× trailing-twelve-month earnings and 1.8× sales.
Return on equity was 38.9% and debt-to-equity 1.10.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.22 (grey zone) for fiscal 2025.